188 related articles for article (PubMed ID: 20233883)
21. CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer.
Assaf C; Gellrich S; Whittaker S; Robson A; Cerroni L; Massone C; Kerl H; Rose C; Chott A; Chimenti S; Hallermann C; Petrella T; Wechsler J; Bagot M; Hummel M; Bullani-Kerl K; Bekkenk MW; Kempf W; Meijer CJ; Willemze R; Sterry W
J Clin Pathol; 2007 Sep; 60(9):981-9. PubMed ID: 17018683
[TBL] [Abstract][Full Text] [Related]
22. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Kamata M; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Clin Cancer Res; 2011 Dec; 17(24):7529-38. PubMed ID: 22048239
[TBL] [Abstract][Full Text] [Related]
23. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782
[TBL] [Abstract][Full Text] [Related]
24. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
[TBL] [Abstract][Full Text] [Related]
25. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
[TBL] [Abstract][Full Text] [Related]
26. Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside.
Damsky WE; Choi J
Curr Treat Options Oncol; 2016 Jul; 17(7):33. PubMed ID: 27262707
[TBL] [Abstract][Full Text] [Related]
27. Cutaneous T-cell lymphoma: molecular and cytogenetic findings.
Sterry W
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):13-7. PubMed ID: 17474354
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
Ellis L; Pan Y; Smyth GK; George DJ; McCormack C; Williams-Truax R; Mita M; Beck J; Burris H; Ryan G; Atadja P; Butterfoss D; Dugan M; Culver K; Johnstone RW; Prince HM
Clin Cancer Res; 2008 Jul; 14(14):4500-10. PubMed ID: 18628465
[TBL] [Abstract][Full Text] [Related]
29. [Malignant lymphoma of the skin].
Burg G; Dommann S; Dummer R
Ther Umsch; 1993 Dec; 50(12):828-34. PubMed ID: 8171405
[TBL] [Abstract][Full Text] [Related]
30. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
[TBL] [Abstract][Full Text] [Related]
31. Controversies in the management of the cutaneous T cell lymphomas.
Zic JA
Dermatol Ther; 2009; 22(5):407-17. PubMed ID: 19845718
[TBL] [Abstract][Full Text] [Related]
32. Primary cutaneous T-cell lymphoma: review and current concepts.
Siegel RS; Pandolfino T; Guitart J; Rosen S; Kuzel TM
J Clin Oncol; 2000 Aug; 18(15):2908-25. PubMed ID: 10920140
[TBL] [Abstract][Full Text] [Related]
33. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior.
Berti E; Tomasini D; Vermeer MH; Meijer CJ; Alessi E; Willemze R
Am J Pathol; 1999 Aug; 155(2):483-92. PubMed ID: 10433941
[TBL] [Abstract][Full Text] [Related]
34. Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma.
Olsen EA
Dermatol Clin; 2015 Oct; 33(4):643-54. PubMed ID: 26433839
[TBL] [Abstract][Full Text] [Related]
35. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
36. Large-cell transformation following detection of minimal residual disease in cutaneous T-cell lymphoma: molecular and in situ analysis of a single neoplastic T-cell clone expressing the identical T-cell receptor.
Wolfe JT; Chooback L; Finn DT; Jaworsky C; Rook AH; Lessin SR
J Clin Oncol; 1995 Jul; 13(7):1751-7. PubMed ID: 7602365
[TBL] [Abstract][Full Text] [Related]
37. The applicability of T-cell receptor gamma gene rearrangement as an adjuvant diagnostic tool in skin biopsies for cutaneous T-cell lymphoma.
Khalil SH; Hamadah IR
Saudi Med J; 2006 Jul; 27(7):951-4. PubMed ID: 16830010
[TBL] [Abstract][Full Text] [Related]
38. Comparative study of cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma.
Nagatani T; Miyazawa M; Matsuzaki T; Iemoto G; Kim ST; Baba N; Miyamoto H; Nakajima H
Semin Dermatol; 1994 Sep; 13(3):216-22. PubMed ID: 7986691
[TBL] [Abstract][Full Text] [Related]
39. Early changes in gene expression of the entire pathological process in Cutaneous T-cell lymphoma.
Li Y; Wang X; Li Y; Ma R; Zhao Z; Ren J; Men J
J Cell Biochem; 2019 Oct; 120(10):17472-17480. PubMed ID: 31106473
[TBL] [Abstract][Full Text] [Related]
40. Utility of flow cytometry and gene rearrangement analysis in tissue and blood of patients with suspected cutaneous T‑cell lymphoma.
Gibbs JD; Ma S; Kim A; Seminario-Vidal L; Sokol L; Zhang H; Zhang X; Sagatys E; Chen PL; Messina JL
Oncol Rep; 2021 Jan; 45(1):349-358. PubMed ID: 33416132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
